Transgene to Present New Positive Preliminary Phase I Clinic

Transgene will discuss new immunogenicity and clinical data generated with TG4050 that reinforce the strong potential of this individualized immunotherapy: Relevant neoantigens could be identified

Related Keywords

Louisiana , United States , New Orleans , Ankara , Turkey , Paris , France General , France , United Kingdom , American , Lucie Larguier , Jean Pierre Delord , Sylvie Berrebi , Christian Ottensmeier , Alexandra Martinez , Christophe Le Tourneau , Le Tourneau , Transgene Euronext , Yujie Zhao , C Le Tourneau , Institut Curie , Head Of The Department Drug Development , Clatterbridge Cancer Centre , Twitter , University Of Liverpool , Astrazeneca , American Association For Cancer Research , Corporate Communications , Head Of Surgical Department , Euronext Paris , American Association , Cancer Research , Serious Adverse Events , Phasei Clinical Trials , Consultant Medical Oncologist , Drug Development , Matthew Block , Consultant Medical Oncology , Consultant Immunology , Associate Professor , Mayo Clinic , Associate Head , Surgical Department , Vaccinia Ankara , Artificial Intelligence , Risk Factors , Universal Registration Document , Transgene , Present , Positive , Reliminary , Hase , Linical , Data , Racr , 022 , Reinforcing , Potential , G4050 ,